CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-07-24). The draft was written by AI, the existence of all 2 cited sources was verified at the original page, and the verdict passed blind grading and adversarial audit. Methodology v0.6.
Verdict No. 1714 · Search date 2026-07-24 · Methodology v0.6

DASH diet,
does it really help with Reduced systolic and diastolic blood pressure?

30-Second Summary
C
Evidence Grade C · 58 · Safety unknown
DASH lowers blood pressure but does not directly establish fewer cardiovascular events
What the
research shows
The DASH diet consistently lowers blood pressure but earns a C. DASH-Sodium randomized 412 participants, and 390 completed the 12-week intervention and entered the completed endpoint analysis. The primary systolic blood pressure endpoint succeeded; low-sodium DASH lowered pressure by 7.1 mm Hg in participants without hypertension and 11.5 mm Hg in those with hypertension versus high-sodium control. A meta-analysis of 30 trials and 5,545 participants confirmed reductions of 3.2 mm Hg systolic and 2.5 mm Hg diastolic. Rule ①-ⓐ applies: improvement limited to surrogate biomarkers, including blood pressure, has a maximum grade of C.
What the
ads claim
Marketing can portray lower blood pressure as direct proof that the diet prevents myocardial infarction or stroke, but hard outcomes were not tested here.
*

Useful facts when choosing a product

  • DASH emphasizes vegetables, fruit, and low-fat dairy while reducing saturated fat.
  • DASH-Sodium provided all food and held body weight stable.
Gap Measurement · Verdict 1714 · C 58
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

Sacks et al. 2001 randomized 412 people to DASH or control diets and crossed each participant through sodium levels. A total of 390 completed 12 weeks, and the primary systolic endpoint succeeded. Filippou et al. 2020 found reductions of 3.2 mm Hg systolic and 2.5 mm Hg diastolic, both P<0.001, across 30 trials and 5,545 participants.

02

Why this is classified as C (58)

Despite a successful primary endpoint in 390 completers after 412 were randomized and replication across 30 trials, blood pressure is a surrogate, so the grade is C with 58 points.

Counterpoint. Evidence for blood pressure management is strong, but it does not justify stopping medicines or guarantee event prevention.

Rejudgment record. Cross-check applied — Rule ①-ⓐ: improvement limited to surrogate biomarkers, including blood pressure, has a maximum grade of C.

Sub-claim grades by effect

This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.

Effect (sub-claim)GradeBasis
Reduced systolic blood pressureCRepeatedly positive but surrogate.
Reduced diastolic blood pressureCPositive in meta-analysis but surrogate.
Reduced blood pressure in hypertensionCThe effect was larger but not a hard outcome.

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Sacks FM et al. 2001Multicenter randomized controlled-feeding trial with crossover sodium levels12Public funding from the United States NIH NHLBI and related institutesPrimary endpoint: systolic blood pressureSucceeded: major diet and sodium comparisons had P values at or below 0.001.Pivotal surrogate-endpoint trial
Filippou CD et al. 2020Systematic review and meta-analysis of randomized trials5,545No funding receivedSystolic and diastolic blood pressureSystolic -3.2 and diastolic -2.5 mm Hg, both P<0.001.Replication of surrogate effects
§

Receipt — 2 References

All 2 cited sources were verified for existence at the original page (as of 2026-07-24).

Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on Blood Pressure of Reduced Dietary Sodium and the Dietary Approaches to Stop Hypertension (DASH) Diet. N Engl J Med. 2001;344(1):3-10. PMID: 11136953. DOI: 10.1056/NEJM200101043440101.
checked
Filippou CD, Tsioufis CP, Thomopoulos CG, et al. Dietary Approaches to Stop Hypertension (DASH) Diet and Blood Pressure Reduction in Adults with and without Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Adv Nutr. 2020;11(5):1150-1160. PMID: 32330233. DOI: 10.1093/advances/nmaa041.
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-24 · Corrections: none

Cite this verdict

DASH diet x lower blood pressure Evidence Grade C card
[Chamgap] DASH diet x lower blood pressure — Evidence Grade C·58. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/heart/dash-diet-blood-pressure/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.